Parkinson's disease: is the initial treatment established?

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Recent studies suggest early dopamine agonist therapy (pramipexole, ropinirole) may slow Parkinson's disease (PD) progression and reduce levodopa motor complications.
• This potential effect on PD progression might be an artifact of chronic drug effects on dopamine system proteins.

Purpose of the Study:

• To evaluate the actual impact of early dopamine agonist therapy on Parkinson's disease progression.
• To clarify the necessity of early initiation of pramipexole or ropinirole versus initiating them after levodopa complications arise.

Main Methods:

• Review of existing studies and clinical data on dopamine agonist and levodopa therapies in Parkinson's disease.
• Analysis of the effects of pramipexole and ropinirole on dopamine system proteins and motor complications.

Main Results:

• Pramipexole and ropinirole are confirmed effective in reducing levodopa-induced dyskinesias and motor fluctuations.
• Evidence for early dopamine agonist therapy slowing PD progression is inconclusive and potentially artifactual.
• Levodopa therapy offers advantages in efficacy, cost, administration, and lower incidence of hallucinations and somnolence.

Conclusions:

• While dopamine agonists effectively manage levodopa complications, their early initiation for disease modification is not definitively proven.
• Carbidopa/levodopa, pramipexole, and ropinirole are all considered appropriate first-line treatments for Parkinson's disease.
• The decision to initiate therapy should consider individual patient factors and the specific benefits of each drug class.